25 Jan 2024 13:16
Diaceutics PLC - Exercise of Warrant & Total Voting Rights
Belfast and London, 25 January 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to pharma and biotech companies, announces that it has received notification for the exercise of warrants over 177,915 ordinary shares of £0.002 each in the Company ("Ordinary Shares") at an exercise price of £0.76 per share, providing the Company with proceeds of £135,215 ("Warrant Exercise").
Application has been made to the London Stock Exchange to admit the 177,915 new ordinary shares resulting from the Warrant Exercise to trading on AIM ("Admission"), which is expected to occur on at 8:00 am tomorrow 26 January 2024. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. The Warrant Exercise completes all outstanding warrants.
Following Admission, the total issued share capital of the Company will consist of 84,679,305 Ordinary Shares. This number may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
Diaceutics PLC?? | |
Ryan?Keeling, Chief Executive Officer | Tel: +44 (0)28 9040 6500 |
Nick Roberts, Chief Financial Officer | investorrelations@diaceutics.com |
Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
Ben Maddison | |
Nick Harland | |
Kate Hanshaw | |
Alma Strategic Communications | Tel: +44(0)20 3405 0205 |
Caroline Forde | diaceutics@almastrategic.com |
Matthew Young | |
Kinvara Verdon |
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.
We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®
Diaceutics (DXRX)